Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease.

Sivendran S, Chang R, Pham L, Phelps RG, Harcharik ST, Hall LD, Bernardo SG, Moskalenko MM, Sivendran M, Fu Y, de Moll EH, Pan M, Moon JY, Arora S, Cohain A, DiFeo A, Ferringer TC, Tismenetsky M, Tsui CL, Friedlander PA, Parides MK, Banchereau J, Chaussabel D, Lebwohl MG, Wolchok JD, Bhardwaj N, Burakoff SJ, Oh WK, Palucka K, Merad M, Schadt EE, Saenger YM.

J Invest Dermatol. 2014 Aug;134(8):2202-11. doi: 10.1038/jid.2014.85. Epub 2014 Feb 12.

2.

Defining the role of CD2 in disease progression and overall survival among patients with completely resected stage-II to -III cutaneous melanoma.

Harcharik S, Bernardo S, Moskalenko M, Pan M, Sivendran M, Bell H, Hall LD, Castillo-Martín M, Fox K, Cordon-Cardo C, Chang R, Sivendran S, Phelps RG, Saenger Y.

J Am Acad Dermatol. 2014 Jun;70(6):1036-44. doi: 10.1016/j.jaad.2014.01.914. Epub 2014 Mar 31.

PMID:
24698703
3.

Gene expression profiling of primary cutaneous melanoma and clinical outcome.

Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A; Melanoma Group of the European Organization for Research and Treatment of Cancer.

J Natl Cancer Inst. 2006 Apr 5;98(7):472-82.

4.

Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data.

Di Narzo AF, Tejpar S, Rossi S, Yan P, Popovici V, Wirapati P, Budinska E, Xie T, Estrella H, Pavlicek A, Mao M, Martin E, Scott W, Bosman FT, Roth A, Delorenzi M.

J Natl Cancer Inst. 2014 Sep 22;106(10). pii: dju247. doi: 10.1093/jnci/dju247. Print 2014 Oct.

5.

Cell cycle gene networks are associated with melanoma prognosis.

Wang L, Hurley DG, Watkins W, Araki H, Tamada Y, Muthukaruppan A, Ranjard L, Derkac E, Imoto S, Miyano S, Crampin EJ, Print CG.

PLoS One. 2012;7(4):e34247. doi: 10.1371/journal.pone.0034247. Epub 2012 Apr 20.

6.

A nine-gene signature predicting clinical outcome in cutaneous melanoma.

Brunner G, Reitz M, Heinecke A, Lippold A, Berking C, Suter L, Atzpodien J.

J Cancer Res Clin Oncol. 2013 Feb;139(2):249-58. doi: 10.1007/s00432-012-1322-z. Epub 2012 Oct 9.

PMID:
23052696
7.
8.

Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival.

Conway C, Mitra A, Jewell R, Randerson-Moor J, Lobo S, Nsengimana J, Edward S, Sanders DS, Cook M, Powell B, Boon A, Elliott F, de Kort F, Knowles MA, Bishop DT, Newton-Bishop J.

Clin Cancer Res. 2009 Nov 15;15(22):6939-46. doi: 10.1158/1078-0432.CCR-09-1631. Epub 2009 Nov 3.

9.

Melanoma MicroRNA signature predicts post-recurrence survival.

Segura MF, Belitskaya-Lévy I, Rose AE, Zakrzewski J, Gaziel A, Hanniford D, Darvishian F, Berman RS, Shapiro RL, Pavlick AC, Osman I, Hernando E.

Clin Cancer Res. 2010 Mar 1;16(5):1577-86. doi: 10.1158/1078-0432.CCR-09-2721. Epub 2010 Feb 23.

10.

Expression profiling of formalin-fixed paraffin embedded primary human uveal melanomas using DASL matrices.

Di Cesare S, Nantel A, Marshall JC, Fernandes BF, Antecka E, Orellana ME, Abourbih D, Saornil AM, Burnier MN Jr.

J Cancer Res Clin Oncol. 2010 Apr;136(4):577-86. doi: 10.1007/s00432-009-0692-3. Epub 2009 Oct 13.

PMID:
19823872
11.

Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis.

Raskin L, Fullen DR, Giordano TJ, Thomas DG, Frohm ML, Cha KB, Ahn J, Mukherjee B, Johnson TM, Gruber SB.

J Invest Dermatol. 2013 Nov;133(11):2585-92. doi: 10.1038/jid.2013.197. Epub 2013 Apr 30.

12.
13.

Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma.

Nguyen T, Kuo C, Nicholl MB, Sim MS, Turner RR, Morton DL, Hoon DS.

Epigenetics. 2011 Mar;6(3):388-94. Epub 2011 Mar 1.

14.

Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases.

Koh SS, Wei JP, Li X, Huang RR, Doan NB, Scolyer RA, Cochran AJ, Binder SW.

Mod Pathol. 2012 Jun;25(6):828-37. doi: 10.1038/modpathol.2012.32. Epub 2012 Mar 9.

15.
16.

Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites.

Essner R, Kuo CT, Wang H, Wen DR, Turner RR, Nguyen T, Hoon DS.

Cancer. 1998 Jan 15;82(2):309-16.

PMID:
9445187
17.

Gene network analyses point to the importance of human tissue kallikreins in melanoma progression.

Martins WK, Esteves GH, Almeida OM, Rezze GG, Landman G, Marques SM, Carvalho AF, L Reis LF, Duprat JP, Stolf BS.

BMC Med Genomics. 2011 Oct 27;4:76. doi: 10.1186/1755-8794-4-76.

18.

The role of osteopontin expression in melanoma progression.

Kiss T, Ecsedi S, Vizkeleti L, Koroknai V, Emri G, Kovács N, Adany R, Balazs M.

Tumour Biol. 2015 Sep;36(10):7841-7. doi: 10.1007/s13277-015-3495-y. Epub 2015 May 7.

PMID:
25944164
19.

Molecular classification of melanomas and nevi using gene expression microarray signatures and formalin-fixed and paraffin-embedded tissue.

Koh SS, Opel ML, Wei JP, Yau K, Shah R, Gorre ME, Whitman E, Shitabata PK, Tao Y, Cochran AJ, Abrishami P, Binder SW.

Mod Pathol. 2009 Apr;22(4):538-46. doi: 10.1038/modpathol.2009.8. Epub 2009 Mar 6.

20.

Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy.

Beard RE, Abate-Daga D, Rosati SF, Zheng Z, Wunderlich JR, Rosenberg SA, Morgan RA.

Clin Cancer Res. 2013 Sep 15;19(18):4941-50. doi: 10.1158/1078-0432.CCR-13-1253. Epub 2013 Sep 10.

Items per page

Supplemental Content

Write to the Help Desk